Short answer
Anika Therapeutics, Inc. (ANIK) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $30M (up 13.2% year over year) with net income of −$5M.
Q1 2026 key financials · XBRL
- Revenue
- $30M
- +13.2% YoY
- Net income
- −$5M
- −3.8% YoY
- Operating margin
- -18.5%
- Gross margin
- 64.2%
- EPS (diluted)
- −$0.37
- −8.8% YoY
Source: XBRL data from the Anika Therapeutics, Inc. (ANIK) Q1 2026 10-Q on SEC EDGAR. USD.
Anika Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $29.6M, up 13% YoY from $26.2M; OEM Channel highest growth at 14%, Commercial Channel up 12%
- Gross margin 64% vs 56% YoY; net loss $5.1M vs $4.9M
- Regenerative revenue up $0.6M, driven by higher Integrity and Hyalofast sales; Tactoset revenue declined
- Cash $41.0M vs $57.5M at December 31; operating cash used $4.9M vs $0.1M
- Share repurchases $8.7M; management expects operating cash flows, cash, and credit availability to fund needs
Risk Factors
- Risk Factors section not provided in submitted filing text
- Share repurchases totaled 774,638 shares during the quarter
- Remaining repurchase authorization declined to $10.583 million by March 31, 2026
- Clear Street repurchase agreement completed in April 2026
- No director or executive officer adopted or terminated trading plans during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Anika Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.